4.7 Article

Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection

Journal

JOURNAL OF INFECTIOUS DISEASES
Volume 220, Issue 2, Pages 254-265

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiz094

Keywords

HIV-1; next-generation sequencing; diversity; infection recency; time since infection

Funding

  1. Swiss National Science Foundation [BSSGI0_155851, 179571, 177499]
  2. SHCS Research Foundation
  3. Yvonne Jacob Foundation
  4. clinical research priority program of the University of Zurich Viral infectious diseases, ZPHI
  5. SystemsX.ch grant HIVX
  6. Gilead
  7. SIB Swiss Institute of Bioinformatics as an SIB Competitive Resource
  8. Swiss National Science Foundation (SNF) [BSSGI0_155851] Funding Source: Swiss National Science Foundation (SNF)

Ask authors/readers for more resources

Background. Human immunodeficiency virus type 1 (HIV-1) genetic diversity increases over the course of infection and can be used to infer the time since infection and, consequently, infection recency, which are crucial for HIV-1 surveillance and the understanding of viral pathogenesis. Methods. We considered 313 HIV-infected individuals for whom reliable estimates of infection dates and next-generation sequencing (NGS)-derived nucleotide frequency data were available. Fractions of ambiguous nucleotides, obtained by population sequencing, were available for 207 samples. We assessed whether the average pairwise diversity calculated using NGS sequences provided a more exact prediction of the time since infection and classification of infection recency (<1 year after infection), compared with the fraction of ambiguous nucleotides. Results. NGS-derived average pairwise diversity classified an infection as recent with a sensitivity of 88% and a specificity of 85%. When considering only the 207 samples for which fractions of ambiguous nucleotides were available, the NGS-derived average pairwise diversity exhibited a higher sensitivity (90% vs 78%) and specificity (95% vs 67%) than the fraction of ambiguous nucleotides. Additionally, the average pairwise diversity could be used to estimate the time since infection with a mean absolute error of 0.84 years, compared with 1.03 years for the fraction of ambiguous nucleotides. Conclusions. Viral diversity based on NGS data is more precise than that based on population sequencing in its ability to predict infection recency and provides an estimated time since infection that has a mean absolute error of <1 year.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Public, Environmental & Occupational Health

Female Genital Mutilation/Cutting in the Swiss HIV Cohort Study: A Cross-Sectional Study

Fabio Mauri, Sara Cottler-Casanova, Matthias Cavassini, Marcel Stoeckle, Gilles Wandeler, Patrick Schmid, Dominique L. Braun, Alexandra Scherrer, Enos Bernasconi, Alexandra Calmy, Jasmine Abdulcadir

Summary: FGM/C is a harmful practice that involves injury to the female genitalia without medical purpose, and it is prevalent worldwide. There is a lack of knowledge on how to care for women with FGM/C, and improvements in care and prevention are needed.

JOURNAL OF IMMIGRANT AND MINORITY HEALTH (2023)

Article Immunology

Polygenic Risk Scores for Prediction of Subclinical Coronary Artery Disease in Persons Living With HIV: The Swiss HIV Cohort Study

Isabella C. Schoepf, Christian W. Thorball, Helen Kovari, Bruno Ledergerber, Ronny R. Buechel, Alexandra Calmy, Rainer Weber, Philipp A. Kaufmann, Rene Nkoulou, Johannes M. Schwenke, Dominique L. Braun, Jacques Fellay, Philip E. Tarr

Summary: In Swiss HIV-infected individuals, subclinical coronary artery disease is independently associated with an individual polygenic risk score for coronary artery disease. Combining non-genetic and genetic cardiovascular risk factors provides the most powerful prediction for subclinical coronary artery disease.

CLINICAL INFECTIOUS DISEASES (2023)

Article Immunology

Hepatitis B Virus (HBV) Replication During Tenofovir Therapy Is Frequent in Human Immunodeficiency Virus/HBV Coinfection

Eveline Hofmann, Bernard Surial, Noemie Boillat-Blanco, Huldrych F. Guenthard, Marcel Stoeckle, Enos Bernasconi, Patrick Schmid, Alexandra Calmy, Franziska Suter-Riniker, Andri Rauch, Gilles Wandeler, Charles Beguelin

Summary: In the Swiss HIV Cohort Study, researchers found that 27% of HIV-suppressed individuals with chronic hepatitis B virus (HBV) infection had HBV replication after two years on tenofovir. However, 77% of them were able to achieve suppression thereafter. Self-reported adherence to therapy and HBV viral load at tenofovir initiation were identified as predictors of persistent replication.

CLINICAL INFECTIOUS DISEASES (2023)

Article Infectious Diseases

Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1

Suraj Balakrishna, Tom Loosli, Maryam Zaheri, Paul Frischknecht, Michael Huber, Katharina Kusejko, Sabine Yerly, Karoline Leuzinger, Matthieu Perreau, Alban Ramette, Chris Wymant, Christophe Fraser, Paul Kellam, Astrid Gall, Hans H. Hirsch, Marcel Stoeckle, Andri Rauch, Matthias Cavassini, Enos Bernasconi, Julia Notter, Alexandra Calmy, Huldrych F. Gunthard, Karin J. Metzner, Roger D. Kouyos

Summary: This study compared the reliability of Sanger sequencing and Next-generation sequencing (NGS) in detecting HIV drug resistance mutations (DRMs). The results showed good agreement between the two methods when detecting mutations at a threshold of 5% or higher. However, at lower thresholds, NGS detected a substantial number of low-frequency mutations, which were likely to be sequencing errors.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Article Immunology

Quantifying and Predicting Ongoing Human Immunodeficiency Virus Type 1 Transmission Dynamics in Switzerland Using a Distance-Based Clustering Approach

Marco Labarile, Tom Loosli, Marius Zeeb, Katharina Kusejko, Michael Huber, Hans H. Hirsch, Matthieu Perreau, Alban Ramette, Sabine Yerly, Matthias Cavassini, Manuel Battegay, Andri Rauch, Alexandra Calmy, Julia Notter, Enos Bernasconi, Christoph Fux, Huldrych F. Gunthard, Chloe Pasin, Roger D. Kouyos

Summary: This study investigated and predicted the dynamics of HIV transmission in Switzerland using a network-based clustering method and statistical learning approaches. The study found that network characteristics can capture major heterogeneities in transmission and that cluster structure has the potential for real-time prediction of ongoing transmission.

JOURNAL OF INFECTIOUS DISEASES (2023)

Article Immunology

Triggers of Change in Sexual Behavior Among People With HIV: The Swiss U = U Statement and COVID-19 Compared

Kalongo Hamusonde, Dunja Nicca, Huldrych F. Gunthard, Marcel Stoeckle, Katharine E. A. Darling, Alexandra Calmy, Enos Bernasconi, David Haerry, Patrick Schmid, Roger D. Kouyos, Andri Rauch, Luisa Salazar-Vizcaya

Summary: We examined the changes in sexual behavior of HIV-positive individuals over a span of 20 years. Since the Swiss U = U statement, the use of condoms with stable partners has consistently decreased from over 90% to 29%, with similar trends observed among men who have sex with men (MSM) and heterosexuals. Despite the COVID-19 pandemic and social distancing measures, MSM have maintained a higher frequency of occasional partnerships compared to heterosexual individuals.

JOURNAL OF INFECTIOUS DISEASES (2023)

Article Immunology

Impact of hepatitis C cure on risk of mortality and morbidity in people with HIV after antiretroviral therapy initiation

Mathieu Chalouni, Adam Trickey, Suzanne M. Ingle, Maria Antonia Sepuvelda, Juan Gonzalez, Andri M. Rauch, Heidi M. Crane, M. John Gill, Peter F. Rebeiro, Jurgen K. Rockstroh, Ricardo A. Franco, Giota Touloumi, Didier Neau, Montserrat Laguno, Michaela Rappold, Colette Smit, Jonathan A. C. Sterne, Linda Wittkop

Summary: Reaching SVR in HIV/HCV co-infected individuals significantly reduces mortality, but there may still be a higher risk of non-AIDS nonliver cancers compared to mono-infected individuals. Monitoring of these events following SVR is necessary.
Article Immunology

Understanding the Decline of Incident, Active Tuberculosis in People With Human Immunodeficiency Virus (HIV) in Switzerland

Marius Zeeb, Burcu Tepekule, Katharina Kusejko, Claudine Reiber, Marisa Kalin, Lena Bartl, Julia Notter, Hansjakob Furrer, Matthias Hoffmann, Hans H. Hirsch, Alexandra Calmy, Matthias Cavassini, Niklaus D. Labhardt, Enos Bernasconi, Dominique L. Braun, Huldrych F. Gunthard, Roger D. Kouyos, Johannes Nemeth

Summary: The incidence of tuberculosis (TB) in people with human immunodeficiency virus type 1 (HIV-1) is decreasing in Switzerland, primarily due to the control of HIV-1 infection and immune system restoration, in addition to TB-specific prevention measures.

CLINICAL INFECTIOUS DISEASES (2023)

Article Immunology

Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study

Hortensia Alvarez, Amanda Mocroft, Lene Ryom, Bastian Neesgaard, Simon Edwards, Veronica Svedhem, Huldrych F. Guenthard, Robert Zangerle, Colette Smith, Antonella Castagna, Antonella d'Arminio Monforte, Ferdinand Wit, Melanie Stecher, Clara Lehman, Cristina Mussini, Eric Fontas, Eva Gonzalez, Jan-Christian Wasmuth, Anders Soennerborg, Stephane De Wit, Nikoloz Chkhartishvili, Christoph Stephan, Kathy Petoumenos, Nadine Jaschinski, Vani Vannappagari, Joel Gallant, Lital Young, Alain Volny Anne, Lauren Greenberg, Raquel Martin-Iguacel, Eva Poveda, Josep M. Llibre

Summary: High baseline HIV RNA levels and low baseline CD4 T-cell counts are associated with higher rates of viral blips, low-level viremia, and residual viremia in individuals treated with integrase inhibitors or specifically with dolutegravir-based regimens, suggesting an independent impact of these characteristics.

CLINICAL INFECTIOUS DISEASES (2023)

Article Obstetrics & Gynecology

Successful implementation of new Swiss recommendations on breastfeeding of infants born to women living with HIV

Pierre Alex Crisinel, Katharina Kusejko, Christian R. Kahlert, Noemie Wagner, Leila Sultan Beyer, Martinez De Tejada, Irene Hosli, Malte Kohns Vasconcelos, Marc Baumann, Katharine Darling, Andrea Duppenthaler, Andri Rauch, Paolo Paioni, Karoline Aebi-Popp

Summary: Swiss national recommendations support HIV-infected women who wish to breastfeed. This study found that the main motivating factors for these women to breastfeed were bonding, neonatal and maternal health benefits. No breastfed infant acquired HIV transmission.

EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2023)

Article Gastroenterology & Hepatology

Contribution of alcohol use in HIV/hepatitis C virus co-infection to all-cause and cause-specific mortality: A collaboration of cohort studies

Adam M. Trickey, Suzanne Ingle, Anders Boyd, M. John Gill, Sophie Grabar, Inma Jarrin, Niels Obel, Giota Touloumi, Robert Zangerle, Andri T. Rauch, Christopher D. Rentsch, Derek J. Satre, Michael Silverberg, Fabrice Bonnet, Jodie Guest, Greer Burkholder, Heidi Crane, Ramon Teira, Juan Berenguer, Christoph Wyen, Sophie Abgrall, Mojgan Hessamfar, Peter Reiss, Antonella A. d'Arminio Monforte, Kathleen McGinnis, Jonathan A. C. Sterne, Linda Wittkop

Summary: Among persons with HIV, higher alcohol use and having hepatitis C virus are associated with increased morbidity and mortality. This study investigated the interaction between alcohol use and hepatitis C virus on mortality in HIV-positive individuals. The results showed a J-shaped pattern of mortality among HIV-positive individuals without hepatitis C virus, with both non-drinkers and heavy drinkers having higher mortality compared to moderate alcohol drinkers. However, among those with hepatitis C virus, only heavy drinkers had higher mortality rates.

JOURNAL OF VIRAL HEPATITIS (2023)

Article Health Care Sciences & Services

Migrating a Well-Established Longitudinal Cohort Database From Oracle SQL to Research Electronic Data Entry (REDCap): Data Management Research and Design Study

Katharina Kusejko, Daniel Smith, Alexandra Scherrer, Paolo Paioni, Malte Kohns Vasconcelos, Karoline Aebi-Popp, Roger D. Kouyos, Huldrych F. Gunthard, Christian R. Kahlert

Summary: The objective of this study was to provide a user-friendly graphical interface for electronic data entry for the Swiss Mother and Child HIV Cohort Study (MoCHiV), using REDCap software. By combining R and REDCap, a systematic pipeline was built to migrate a multicenter longitudinal cohort study from Oracle SQL to REDCap.

JMIR FORMATIVE RESEARCH (2023)

Article Biochemistry & Molecular Biology

Targeted shock-and-kill HIV-1 gene therapy approach combining CRISPR activation, suicide gene tBid and retargeted adenovirus delivery

Sarah Klinnert, Corinne D. Schenkel, Patrick C. Freitag, Huldrych F. Guenthard, Andreas Plueckthun, Karin J. Metzner

Summary: This study uses gene therapy to target and eliminate cells infected with HIV-1 by activating latent virus and killing the cells. This targeted gene therapy approach has the potential to effectively and safely eliminate infected cells.

GENE THERAPY (2023)

Article Infectious Diseases

Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy

Lorin Begre, Anders Boyd, Luisa Salazar-Vizcaya, Franziska Suter-Riniker, Charles Beguelin, Juergen K. Rockstroh, Huldrych F. Guenthard, Alexandra Calmy, Matthias Cavassini, Marcel Stoeckle, Patrick Schmid, Enos Bernasconi, Massimo Levrero, Fabien Zoulim, Gilles Wandeler, Andri Rauch, Swiss HIV Cohort Study SHCS

Summary: In HIV patients with HBsAg loss, qHBsAg levels decline rapidly at the beginning and then show diverse trajectories during long-term tenofovir therapy. In patients without HBsAg loss, qHBsAg levels remain relatively stable over time.

HIV MEDICINE (2023)

Article Critical Care Medicine

Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial

Marius Troseid, Jose R. Arribas, Lambert Assoumou, Aleksander Rygh Holten, Julien Poissy, Vida Terzic, Fulvia Mazzaferri, Jesus Rodriguez Bano, Joe Eustace, Maya Hites, Michael Joannidis, Jose-Artur Paiva, Jean Reuter, Isabel Puentmann, Thale D. J. H. Patrick-Brown, Elin Westerheim, Katerina Nezvalova-Henriksen, Lydie Beniguel, Tuva Borresdatter Dahl, Maude Bouscambert, Monika Halanova, Zoltan Peterfi, Sotirios Tsiodras, Michael Rezek, Matthias Briel, Serhat Unal, Martin Schlegel, Florence Ader, Karine Lacombe, Cecilie Delphin Amdal, Serge Rodrigues, Kristian Tonby, Alexandre Gaudet, Lars Heggelund, Joy Mootien, Asgeir Johannessen, Jannicke Horjen Moller, Beatriz Diaz Pollan, Anders Aune Tveita, Anders Benjamin Kildal, Jean-Christophe Richard, Olav Dalgard, Victoria Charlotte Simensen, Aliou Balde, Lucie de Gastines, Marta del Alamo, Burc Aydin, Fridtjof Lund-Johansen, Mary-Anne Trabaud, Alpha Diallo, Bente Halvorsen, John-Arne Rottingen, Evelina Tacconelli, Yazdan Yazdanpanah, Inge C. Olsen, Dominique Costagliola

Summary: The study conducted a placebo-controlled trial of baricitinib in severe/critical COVID cases. The results showed that baricitinib did not reduce mortality within 60 days, and there may be safety risks in vaccinated participants, which require further investigation.

CRITICAL CARE (2023)

No Data Available